SOURCES SOUGHT
A -- Alpha Virus
- Notice Date
- 5/15/2013
- Notice Type
- Sources Sought
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014
- ZIP Code
- 21702-5014
- Solicitation Number
- 0010310544
- Response Due
- 5/31/2013
- Archive Date
- 7/14/2013
- Point of Contact
- Ryan Jorgensen, 301-619-2359
- E-Mail Address
-
US Army Medical Research Acquisition Activity
(ryan.jorgensen@us.army.mil)
- Small Business Set-Aside
- N/A
- Description
- Sources Sought Memo: This is a Market Research, Sources Sought synopsis for information and planning puposes only and is not to be construed as a commitment by the Government. No contract will be awarded as a result of this sources sought. No reimbursement will be made for any cost associated with providing information in response to this solicitation. The United States Army Medical Research Acquisition Activity (USAMRAA) is soliciting on behalf of the United States Medical Research Institue of Infectious Disease (USAMRIID) information from potential qualified businessses. This is a non-personal services contract to provide Scientific, Technical, and Administrative Support Services. The Government shall not exercise any supervision or control over the Contract Service Providers (CSPs) performing the services herein. Such CSPs shall be accountable solely to the Contractor who, in turn, is responsible to the Government. Back ground and Descritption of Required Work: No FDA approved medical countermeasures exist to treat alphavirus infection and the development of potential therapeutics remains a high priority for the military. Currently, USAMRIID and Zalicus are funded to screen a library of FDA approved compounds for their effectiveness against encephalitic and viral hemorrhagic fever viruses. They have identified several promising candidates that warrant further characterization. However, the specific mechanism of action and in vivo effectiveness is unknown. These studies are needed as the initial steps for necessary preclinical evaluation that will lead to advanced development efforts. Therefore, the objective of this work is to further characterize and determine the mechanism of action of lead FDA approved compounds found to be effective during initial in vitro alphavirus screening efforts. Tasks/Technical Requirements: 1: Characterize the potency and effectiveness of the candidate compounds in vitro and in vivo. 1.1: Confirm the antivirus activity of the lead compounds (5-10 candidates) against VEEV by a yield reduction assay. 1.2: Select compounds to be assessed in vivo in mice (compounds with greater than 1 logio PFU/mL reduction in virus compared to no compound control). 1.3: Assess the effectiveness of the lead compounds in mice using a virus construct that expresses luciferase to directly measure the effectiveness of the compounds using an in vivo imaging system. 1.4: Identification of lead compounds with in vitro and in vivo efficacy (deliverable 1, milestone 1). 2: Determine the mechanism of action of lead compounds identified in the above tasks. 2.1: Complete a virucidal assay for lead compounds to determine if they possess virus-inactivating activity. 2.2: Complete a pretreatment assay for lead compounds to determine their effect on host cells. 2.3: Complete attachment and penetration assays for lead compounds to investigate if the compounds interfere with the early stages of viral infection. 2.4: Complete time of addition and removal assays for lead compounds to provide insight about the compounds effect on the various stages of virus replication. 2.5: Complete a virus release assay for lead compounds to determine their ability to interfere with virus release. 2.6: Complete additional assays as needed depending on the results of the above assays (i.e. determining the effects of the lead compounds on viral gene expression protein synthesis, anti-ATPase assay). 2.7: Provide the proposed mechanism of action of lead compounds. Interested parties shall submit a Capability Statement that clearly addresses your corporate capabilities The capability statement is not to exceed 10 pages and shall at a minimum address the following: (1) Name of Company; (2) Company Address; (3) Point of Contact Information: (4) Company Size: (5) Describe experience and past performance with similar types of requirements of similar scope and magnitude and whether they were performed performance-based and include the contract number, Government agency name and address and contract funded amount; (6) Identify qualifications of technical and management personnel. THIS SYNOPSIS IS FOR INFORMATION PLANNING PURPOSES ONLY AND IS NOT A COMMITMENT BY THE GOVERNMENT. THIS IS NOT A SOLICITATION ANNOUNCEMENT FOR PROPOSALS AND A CONTRACT WILL NOT BE AWARDED FROM THIS ANNOUNCEMENT. NO REIMBURSEMENT WILL BE MADE FOR ANY COSTS ASSOCIATED WITH PROVIDING INFORMATION IN RESPONSE TO THIS ANNOUNCEMENT AND ANY FOLLOW-UP INFORMATION REQUESTS. All responses must be submitted by email to the point of contact identified below; no other method of transmittal will be accepted. This is a new work effort. Respondents submitting a capability statement must do so by email NLT: 12:00 P.M., May 31, 2013, attention Ryan Jorgensen, email: ryan.jorgensen@us.army.mil In the Subject line of the email, please reference: Alpha Virus Sources Sought
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/0010310544/listing.html)
- Place of Performance
- Address: US Army Medical Research Acquisition Activity ATTN: MCMR-AAA, 820 Chandler Street Frederick MD
- Zip Code: 21702-5014
- Zip Code: 21702-5014
- Record
- SN03063457-W 20130517/130515235821-1d431da9361404debc4de3a78a16a9c5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |